Enzymatic autoantibody glycan hydrolysis alleviates autoimmunity against type VII collagen  by Hirose, Misa et al.
at SciVerse ScienceDirect
Journal of Autoimmunity 39 (2012) 304e314Contents lists availableJournal of Autoimmunity
journal homepage: www.elsevier .com/locate/ jaut immEnzymatic autoantibody glycan hydrolysis alleviates autoimmunity against type
VII collagen
Misa Hirose a, Katerina Vaﬁa a, Kathrin Kalies b, Stephanie Groth a, Jürgen Westermann b, Detlef Zillikens a,
Ralf J. Ludwig a, Mattias Collin d, Enno Schmidt a,c,*
aDepartment of Dermatology, University of Lübeck, Ratzeburger Allee 160, Lübeck D-23538, Germany
b Institute of Anatomy, University of Lübeck, Ratzeburger Allee 160, Lübeck D-23538, Germany
cComprehensive Center for Inﬂammation Medicine, University of Lübeck, Ratzeburger Allee 160, Lübeck D-23538, Germany
dDivision of Infection Medicine, Department of Clinical Science, Lund University, SE-22184 Lund, Swedena r t i c l e i n f o
Article history:
Received 11 December 2011
Received in revised form
4 April 2012
Accepted 12 April 2012
Keywords:
Autoantibody
Bullous
EndoS
IgG
Hydrolysis* Corresponding author. Department of Dermatolo
zeburger Allee 160, D-23538 Lübeck, Germany. Tel.: þ
(0)451 500 2981.
E-mail address: enno.schmidt@uk-sh.de (E. Schmi
0896-8411  2012 Elsevier Ltd.
doi:10.1016/j.jaut.2012.04.002
Open access under CC BYa b s t r a c t
Autoantibody-mediated diseases comprise a heterogeneous group of disorders in which the pathogenic
potential of autoantibodies has been clearly demonstrated. In general, their treatment relies on the long-
term use of systemic corticosteroids and other immunosuppressants that are associated with consid-
erable adverse reactions. EndoS, an endoglycosidase derived from Streptococcus pyogenes, speciﬁcally
hydrolyzes the N-linked glycan of native IgG and has previously been shown to modulate the interaction
between the Fc portion of autoantibody and Fcg receptors on leukocytes. Here, different models of
autoimmunity to type VII collagen, a structural protein of the dermal-epidermal junction (DEJ), were
employed to explore the therapeutic potential of EndoS. First, pretreatment of otherwise pathogenic
anti-murine type VII collagen (mCOL7) IgG with EndoS signiﬁcantly reduced split formation at the DEJ in
cryosections of murine skin and abrogated clinical disease in mice. Next, the effect of EndoS was also
seen when the enzyme was injected into mice after pathogenic anti-mCOL7 IgG had been administered.
Finally, to mimic the patient situation even closer, EndoS was applied in mice that had already developed
clinical disease after immunization with mCOL7. In all EndoS-treated mice, disease progression was
stopped, and in the majority of mice, clinical disease even regressed. Of note, EndoS was shown to
hydrolyze already in vivo-bound pathogenic autoantibodies. In addition, EndoS treatment decreased
lesional expression of activating FcgRs while increasing FcgRIIB expression.
 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Autoantibody-mediated autoimmune diseases comprise
a heterogeneous group of disorders in which the pathogenic rele-
vance of autoantibodies has been demonstrated, e.g. immune-
mediated thrombocytopenia, ANCA-mediated vasculitis, primary
progressive multiple sclerosis, Sjögren’s syndrome, anti-
phospholipid syndrome, systemic lupus erythematosus, rheuma-
toid arthritis as well as pemphigus and pemphigoid diseases [1,2].
Pemphigus and pemphigoid diseases are characterized by autoan-
tibodies against desmosomal and hemidesmosomal antigens,
respectively [3e5]. The hemidesmosomal proteins collagen type VIIgy, University of Lübeck, Rat-
49 (0)451 500 2538; fax: þ49
dt).
-NC-ND license.and XVII have been identiﬁed as target antigens of epidermolysis
bullosa acquisita (EBA) and bullous pemphigoid, respectively [6e9].
The role of autoantibodies against collagen type VII and XVII has
clearly been established [10e14].
Type VII collagen is a major component of anchoring ﬁbrils in
the basal membrane zone of the skin and mucous membranes with
squamous epithelia [15,16]. Epitopes recognized by the majority of
EBA sera were mapped to the non-collagenous (NC) 1 domain of
type VII collagen [17e19]. We and others have shown the patho-
genic relevance of anti-type VII collagen antibodies by several
in vitro and in vivo models. Speciﬁcally, anti-type VII collagen
antibodies from EBA patients induced dermal-epidermal separa-
tion in cryosections of human skin [20], rabbit and patients type VII
collagen-speciﬁc IgG reproduced the clinical and immunopatho-
logical features of the human disease when passively transferred
into mice [11,21,22], and immunization of certain mouse strains
with a recombinant fragment of the murine NC1 domain of type VII
collagen resulted in a blistering phenotype closely resembling
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bodies to its target antigen alone was not sufﬁcient for lesion
formation but complement activation, the recruitment and acti-
vation of leukocytes, and the release of proteases, that ﬁnally led to
the dermal-epidermal separation, were essential [24e26]. The
central role of the Fc portion of anti-type VII collagen IgG was
shown by the lack of pathogenicity of both rabbit F(ab’)2 fragments
and chicken IgY against anti-type VII collagen [11,27].
The glycosylation status of the Fc portion of IgG is important for
interaction with Fcg receptors (FcgRs). In fact, hydrolysis of IgG
glycan reduces the binding ability to FcgRs in both humans and
mice [28,29]. EndoS, derived from Streptococcus pyogenes, is an
endoglycosidase that hydrolyzes the conserved N-linked glycan on
IgG heavy chains [30e32]. To date, EndoS is the only known
endoglycosidase that exclusively hydrolyzes the glycan of native
IgG [32,33].
Treatment of most autoantibody-mediated diseases, including
EBA, is largely unspeciﬁc and relies on the long-term use of
systemic corticosteroids and additional immunosuppressants that
is frequently associated with severe adverse reactions. Thus, novel
therapeutic avenues are warranted and indeed, EndoS has previ-
ously been successfully applied in experimental autoimmune
diseases, including rheumatoid arthritis [34] and immune-
mediated thrombocytopenia [32]. However, the effect of EndoS
on autoantibodies that have already bound to their target antigens
and that have already induced clinical disease has not yet been
addressed.
Here, we showed that EndoS signiﬁcantly reduced the patho-
genic effect of autoantibodies to type VII collagen in 3 different
experimental models. Importantly, closely mimicking the patient
situation, EndoS suppressed disease activity in the immunization-
induced mouse model, even when applied after anti- collagen
type VII antibodies had bound to the skin and clinical disease had
developed. Extending the present knowledge of the action of EndoS
the enzyme was shown to hydrolyze already in vivo-bound path-
ogenic autoantibodies and to differentially modulate the expres-
sion of activating and inhibiting FcgRs.2. Materials and methods
2.1. Generation of rabbit antibodies to murine collagen type VII
(mCOL7)
Pathogenic IgG was generated as previously described [11]. In
brief, New Zealand white rabbits were immunized with recombi-
nant forms of the glutathione S-transferase (GST)-tagged NC1
domain of mCOL7 and the rabbit serum was puriﬁed by afﬁnity
chromatography using protein G. Reactivity of IgG fractions was
analyzed by indirect immunoﬂuorescence (IF) microscopy on
murine (BALB/c) skin. In parallel, rabbit IgG against GST alone was
prepared.2.2. EndoS preparation and IgG hydrolysis in vitro
Recombinant GST-tagged EndoS was expressed in Escherichia
coli as previously described [33]. One mg of rabbit anti-mCOL7 IgG
was incubated with 5 mg recombinant GST-EndoS in PBS for 16 h at
37 C followed by afﬁnity removal of GST-EndoS by serial passages
over Glutathione-Sepharose 4B columns (GE Healthcare, Uppsala,
Sweden). This GST-EndoS-treated IgG is called EndoS-pretreated
IgG throughout the paper. Prior treatment of animals, the GST-tag
was removed from GST-EndoS using factor Xa (Novagen, Madi-
son,WI). Liberated GSTand factor Xawas removed by serial passage
over Xarrest agarose (Novagen) and Glutathione-Sepharose 4B.2.3. IgG puriﬁcation, SDS-PAGE, and lectin blotting
For sodium dodecyl sulphate polyacrylamide gel electrophoresis
(SDS-PAGE) and lectin blot analyses, total IgG was puriﬁed from
10 ml mouse serum samples using Ab SpinTrap (GE Healthcare)
according to manufacturer’s instructions. SDS-PAGE and immuno-
blotting were performed as previously described [32]. Glycosylated
IgG was detected by using 5 mg/ml biotinylated Lens culinaris
agglutinin (LCA)-lectin (Vector Laboratories, Burlingame, CA) and
1 mg/ml streptavidinehorseradish peroxidase (Vector Laboratories)
and Super Signal West Pico peroxidase substrate (Pierce, Rockford,
IL). Membranes were analyzed by using a Chemidoc XRS imaging
system and Quantity One image analysis software (BioRad,
Hercules, CA).
2.4. Cryosection assay
Skin dermal-epidermal separation was evaluated using an
ex vivo model as previously described [35]. Brieﬂy, leukocytes from
the peripheral blood of healthy volunteers were isolated by a sedi-
mentation gradient containing sodium diatrizoate and dextran 500
following the instructions of the manufacturer (Nycomed, Oslo,
Norway), then harvested and washed twice in RPMI 1640 (Life
Technologies, Karlsruhe, Germany) and resuspended in the same
medium. The cell suspension was kept on ice and cell viability was
tested using trypan blue; preparations with viability greater than
95% were used. Cryosections prepared from adult mouse tail skin
(BALB/c) were placed in the center of a Superfrost Plus microscope
slide (Menzel-Glaser, Braunschweig, Germany). Skin sections were
washed with PBS for 5 min to remove embedding medium, then
incubated with 50 ml of 1:2 diluted either EndoS-pretreated anti-
mCOL7 IgG or non-treated anti-mCOL7 IgG for 90 min at room
temperature. After washing the sections with PBS twice, chambers
were prepared as described and the leukocyte suspension at the
concentration of 1  107 cell/ml was injected into the chambers.
Subsequently, chambers were disassembled, and sections were
washed in PBS, ﬁxed in formalin, and stained with hematoxylin and
eosin. Finally, skin dermal-epidermal separation was evaluated
microscopically and the extent expressed as the proportion of the
epidermis detached from the dermis. Approval for these studies
was obtained from the Institutional Review board at the University
of Lübeck (Lübeck, Germany 09-140), and informed consent was
provided according to the Declaration of Helsinki.
2.5. Induction of autoimmunity to mCOL7
2.5.1. Animals
Six to 8 week-old BALB/c mice for passive EBA model and SJL for
active EBA model were purchased from Charles River (Sulzfeld,
Germany). Animals were housed at 12 h lightedark cycle at the
experimental animal facility in the University of Lübeck. All clinical
examinations, biopsies and bleedings were performed under
anesthesia using intraperitoneal administration of a mixture of
ketamine (100 mg/g) and xylazine (15 mg/g). Animal experiments
were approved by local authorities of the Animal Care and Use
Committee (Kiel, Germany; 68-6/09) and performed by certiﬁed
personnel.
2.5.2. Passive transfer model
Passive transfer studies followed a previously published
protocol [11] with minor modiﬁcations. Brieﬂy, mice received
7.5 mg of rabbit anti-mCOL7 IgG or EndoS-pretreated rabbit anti-
mCOL7 IgG subcutaneously in abdominal skin every other day
from day 0 in total of 6 injections. Alternatively, EndoS was injected
i.p. 24 h after anti-mCOL7 IgG injections. Mice were evaluated at 4
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injection (day 12). Cutaneous lesions were counted, and the extent
of skin disease was scored as involvement of the skin surface as
reported previously [11]. At the same time intervals, blood was
obtained for analysis of circulating antibodies. At day 12, all mice
were sacriﬁced, blood was taken, and both lesional and perilesional
biopsies were taken for histopathological analysis (stored in 4%
buffered formalin) and perilesional biopsies were direct IF
microscopy for determination of IgG and C3 deposits at the DEJ
(stored at 80 C), respectively.
2.5.3. Immunization-induced model
Immunization-induced autoimmunity to mCOL7 was generated
as previously reported [36,37]. In brief, SJL mice were immunized at
the hind footpad with 60 mg of recombinant murine type VII
collagen immunodominant peptide emulsiﬁed in the non-ionic
block copolymer adjuvant TiterMax (ALEXIS Biochemicals, Lör-
rach, Germany). When mice had developed disease with a clinical
score greater 2, they were randomly allocated into 3 experimental
groups (week 0). Two groups were injected intraperitoneally with
200 mg EndoS and 400 mg EndoS, respectively, once a week for 4Fig. 1. EndoS-treated pathogenic IgG did not induce separation at the dermal-epidermal ju
treated (a) and EndoS-pretreated (b) rabbit anti-mCOL7 IgG. After addition of granulocyt
were recruited along the DEJ in sections incubated with untreated compared to sections
triangles (D) indicate the DEJ. After an incubation period of 3 h, signiﬁcantly less subepiderm
(d) compared to sections incubated with EndoS-treated rabbit anti-mCOL7 IgG (e). The size
incubated sections compared with non-treated rabbit anti-mCOL7 IgG (f). *p < 0.05 (t-tes
separation. For the neutrophil binding evaluation, one experiment in triplicate was perform
section with high power view (400) and of DEJ separation was evaluated by two blindedweeks. Mice were clinically evaluated at a week intervals for
presence of skin lesions until week 4; at the same time blood was
taken. Cutaneous lesions were counted, and the extent of skin
disease was scored as involvement of the skin surface as reported
previously [23]. At the end of week 4, biopsies were taken and
blood was drawn as described above for the passive transfer model.
Circulating autoantibodies against mCOL7 were detected by ELISA
as previously described [37].
2.6. Histopathology
Formalin-ﬁxed skin samples were processed into parafﬁn
blocks. 4 mm sections were stained with hematoxylin and eosin
according to standard protocols [37].
2.7. Immunohistochemistry
Six mm cryosections of lesional skin obtained from mice were
ﬁxed in acetone at 20 C for 10 min. Air dried sections were
washed with PBS for 5 min 3 times and incubated with Dako Dual
Endogenous Enzyme Block (DakoCytomation, Hamburg, Germany)nction (DEJ) of normal mouse skin ex vivo. Six mm cryosections incubated with non-
es from healthy volunteers for a 1 h incubation time, signiﬁcantly more neutrophils
incubated with EndoS-treated rabbit anti-mCOL7 IgG (c; ***p < 0.001, t-test). White
al split formation was seen in sections incubated with untreated rabbit anti-mCOL7 IgG
of separation at the DEJ is signiﬁcantly less in EndoS-pretreated rabbit anti-mCOL7 IgG
t). The experiment was conducted six times in triplicate for the evaluation of the DEJ
ed. The extent of neutrophil binding at the DEJ of the two random areas of the entire
observers.
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peroxidase. To reduce non-speciﬁc binding of secondary antibody,
sections were incubated with 5% normal rabbit serum for 20 min at
RT. After excess serum from sections was blotted, sections were
incubated with rat anti-mouse Ly-6C/ly-6G (Gr-1; RB56-8C5, BD
Pharmingen, San Diego, CA, USA) antibody (1:200 dilution in 2%
normal rabbit serum/PBS) for 1 h at RT. Slides were washed with
PBS followed by incubation with rabbit anti-rat IgG (1:200 dilution
in 2% normal rabbit serum/PBS; DakoCytomation) for 45 min at RT.
After washing, sections were incubated with R.T.U. VECTASTAIN
Elite ABC Reagent (Vector Laboratories) for 30min at RT. To develop
the peroxidase reaction, sections were incubated in HistoGreen
(LINARIS, Wertheim-Bettingen, Germany) solution until appro-
priate color developed. Excess solution was washed in tap water,
followed by counterstaining with hematoxylin and sections were
mounted.
2.8. Immunoﬂuorescence (IF) microscopy
Direct IF microscopy to detect tissue-bound IgG, complement C3
deposits has been described previously [23]. Staining intensity of
immunoreactants at the DEJ was quantiﬁed with ImageJ software
(http://rsbweb.nih.gov/ij/). Six mm sections of healthy BALB/c
mouse skin were prepared for indirect IF microscopy to evaluate
tissue binding ability of rabbit anti-mCOL7 IgG andmouse sera [37].
Binding of autoantibodies and C5 to the skin was visualized using
FITC-conjugated rabbit anti-mouse IgG and the monoclonal anti-
mouse C5 antibody BB5.1, respectively (Dako and Cell Sciences,
Canton, MA, USA).
2.9. Quantitive reverse transcriptase-polymerase chain reaction
(RT-PCR)
To evaluate the FcgR and inﬂammatory cytokine expression in
the skin, total RNA was isolated from the half of the right ear
according to the manufacturer’s protocol (Analytic Jena Ag, Neu
Ruppin, Germany). The RNA was incubated with DNase Icl
l
∗∗
∗∗∗
a
r
Fig. 2. EndoS-pretreatment of anti-mCOL7 IgG failed to induce clinical disease in vivo. BALB
untreated rabbit anti-mCOL7 IgG (n ¼ 11) every other day over 12 days (total 45 mg). Clin
affected by lesions. Mice injected with EndoS-pretreated rabbit anti-mCOL7 IgG demonstrat
anti-mCOL7 IgG alone (a; ***p < 0.001, **p < 0.01, t-test). Representative clinical pictures o
mCOL7 IgG (c) at day 12.(SigmaeAldrich Chemie, Munich, Germany) for 15 min and fol-
lowed by heating at 70 C for 10 min, then immediately cooled on
ice. After reverse transcription the cDNA was added to the qPCR
Master Mix Plus SYBR Green I (Eurogentec, Cologne, Germany) and
ampliﬁed using the SDS ABI 7900 system (Applied Biosystems,
Darmstadt, Germany). The forward and reverse primes were
designed by using the computer software CloneManager (Sci Ed
Central, Version7.01; Cary, NC, USA). The optimal primmer
concentrations used were 500 nM each for the forward and reverse
primers (biomers.net, Ulm, Germany). Primers used for this project
are shown in Supplementary Table 1. The same batch of cDNA
(20 ml) was used to determine the cycles of threshold (ct), and the
amount of the cytokine cDNA copies were normalized to the house
keeping gene MLN51.2.10. Autoantibody elution from the skin
Mice (n ¼ 4) were injected twice with rabbit anti-mCOL7 IgG at
day 0 and 2. On day 4, two mice were injected with EndoS 400 mg
and the other two mice remained untreated. Twenty-four hours
later (day 5) mice were sacriﬁced and skin was sampled and
at80 C. Ten mm sections were prepared and placed on Superfrost
Plus microscope slides (Menzel-Glaeser). After removing bedding
medium bywashingwith PBS, antibodies were eluted from the skin
washing with 0.1M glycin, pH 2.8 at 4 C as described previously
[38]. The collected antibodies were neutralized with TriseHCl and
concentrated (Millipore, Cork, Ireland and Vivaspin 500, Sartorius
Stedim, Goettingen, Germany). Autoantibody binding was veriﬁed
by indirect IF microscopy on mouse skin.2.11. Statistical analysis
Sigma plot 11.0 (Systat Software, Inc, Chicago, USA) was used to
perform statistical analysis. A p-value of <0.05 was considered
statistically signiﬁcant. Applied tests are indicated at the respective
table or ﬁgure legends.∗∗∗
b
c
/c mice were subcutaneously injected with 7.5 mg per head EndoS-treated (n ¼ 8) and
ical scores were evaluated every 4 days and determined as the extent of body surface
e a signiﬁcantly lower clinical score compared with mice that received untreated rabbit
f mice injected with untreated rabbit mCOL7 IgG (b) or EndoS-pretreated rabbit anti-
∗∗
a
b
cl
l
r
Fig. 3. Treatment of EndoS following injection of pathogenic IgG suppressed disease
severity in vivo. EndoS was applied at a dose of 10 mg/injection (n ¼ 8) or 100 mg/
injection (n ¼ 8), respectively, every other day, starting at day 1 until day 11, 24 h after
rabbit anti-mCOL7 IgG injection. Disease severity was signiﬁcantly milder in mice that
had received 100 mg EndoS in conjunction with rabbit anti-mCOL7 IgG compared to
mice that had received rabbit anti-mCOL7 IgG alone. (a; **p < 0.01, One-way ANOVA).
The IgG glycan status of serum was analyzed in all mice obtained at day 12. SDS-PAGE
(Stain) and Lens culinaris agglutinin (LCA) lectin blotting conﬁrmed that in the 100 mg
EndoS group and, to a lesser extent, in the 10 mg Endo group, IgG was considerably less
hydrolyzed compared to IgG from untreated mice. Results form 8 individual mice of
each group are shown. Blots were performed in the same experiment including the
appropriate controls and were rearranged for better comparison (b).
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3.1. Hydrolyzed anti-mouse type VII collagen IgG did not change the
binding capacity to its target antigen in vitro
The IgG glycan hydrolyzing effect of EndoS treatment was
veriﬁed by SDS-PAGE and Lens culinaris agglutinin (LCA) lectin blot
analysis before EndoS-treated IgG was applied in further experi-
ments. After successful IgG glycan hydrolysis, SDS-PAGE and LCA
lectin blot analysis showed a reduction of the molecular size of the
heavy chain of rabbit anti-mouse type VII collagen (mCOL7) IgG by
approximately 3 kDa and a strongly reduced signal of the EndoS-
treated rabbit anti-mCOL7 IgG compared to untreated IgG,
respectively (Supplementary Fig. 1). Serial dilutions of EndoS-
treated and untreated anti-mCOL7 IgG used in equal concentra-
tions resulted in the same titer (1:51,200) and binding pattern by
indirect immunoﬂuorescence (IF) microscopy on mouse skin (data
not shown). Thus, hydrolyzation by EndoS did not affect the F(ab’)2
fragment function, i.e. the binding of anti-anti-mCOL7 IgG to the
dermal-epidermal junction (DEJ).
3.2. EndoS-pretreatment of otherwise pathogenic IgG failed to
induce dermal-epidermal separation ex vivo
To evaluate the effect of EndoS treatment, cryosections of
normal mouse skinwere incubated in vitro with EndoS-treated and
untreated rabbit anti-mCOL7 IgG, respectively. After addition of
granulocytes from healthy volunteers for a 1 h incubation time,
signiﬁcantly more neutrophils were recruited along the DEJ in
sections incubated with untreated compared to sections incubated
with EndoS-treated anti-mCOL7 IgG (Fig. 1aec; p < 0.001). After an
incubation period of 3 h, signiﬁcantly less subepidermal split
formation was observed in sections incubated with EndoS-treated
IgG compared to sections incubated with untreated anti-mCOL7
IgG (Fig. 1def; p < 0.05).
3.3. EndoS-pretreatment of otherwise pathogenic IgG failed to
induce clinical disease in vivo
Since the ex vivo pathogenicity of rabbit anti-mCOL7 IgG was
abrogated after treatment with EndoS, the next set of experiences
addressed the in vivo effect of EndoS treatment. BALB/c mice were
subcutaneously injectedwith 7.5mg per head EndoS-treated (n¼ 8)
anduntreated anti-mCOL7 IgG (n¼ 11) every other dayover 12 days.
Mice injected with EndoS-treated IgG (Fig. 2c) did not develop
clinical diseasewhile, as expected, mice injectedwith untreated IgG
(Fig. 2b) developed severe skin lesion reproducing the human
disease (Fig. 2a). These data were obtained from 2 independent
experiments with different anti-mCOL7 IgG preparations.
3.4. Treatment of EndoS following injection of pathogenic IgG
suppressed disease severity in vivo
To evaluate the effect of EndoS in vivo, BALB/c mice received
intraperitoneal EndoS every other day, starting at day 1 until day 11,
at a dose of 10 mg/injection (n ¼ 8) or 100 mg/injection (n ¼ 8) 24 h
after anti-mCOL7 IgG injection. Disease severity was signiﬁcantly
milder in mice that had received 100 mg EndoS in conjunction with
anti-mCOL7 IgG compared to bothmice that had been injectedwith
10 mg EndoS plus anti-mCOL7 IgG and mice that had received anti-
mCOL7 IgG alone (Fig. 3a). The IgG glycan status of mouse serum
was analyzed in all mice at day 12. SDS-PAGE and LCA lectin blot-
ting conﬁrmed that IgG from all EndoS-treated mice was signiﬁ-
cantly less glycosylated compared to IgG from mice that had not
been treated with EndoS (Fig. 3b).3.5. Autoantibody-mediated intralesional inﬂammatory responses
were inhibited by EndoS
The inﬂammatory response in skin lesions of mice was subse-
quently analyzed by histopathology and quantiﬁcation of mRNA for
different cytokines, chemokines, and cellular markers, including
M. Hirose et al. / Journal of Autoimmunity 39 (2012) 304e314 309FcgR, by RT-PCR. By histopathology of biopsies from mouse ears,
signiﬁcantly less inﬂammatory cells were observed in the dermis of
both mice that had received EndoS-pretreated anti-mCOL7 IgG
(n ¼ 8) and mice had been injected with EndoS along with anti-
mCOL7 IgG (n ¼ 8) compared to mice that were injected with
anti-mCOL7 IgG alone (n¼ 11; Fig. 4aec). Also, mRNA levels of T cell
(CD3), dendritic cell (CD11c), macrophage and monocyte markers
(Mac-1) as well as of chemokines (KC, MIP) and inﬂammatory
cytokines (TNFa, and IL-1b) were signiﬁcantly lower in skin of mice
that had received EndoS-pretreated anti-mCOL7 IgG (n ¼ 8)
compared to mice that had obtained untreated anti-mCOL7 IgG
(n ¼ 11; p < 0.001 for CD3, KC, MIP, and IL-1b, p < 0.05 for CD11c,
p < 0.01 for TNFa; Fig. 4d). In contrast, mRNA levels of IFN-g,
RANTES, and IL-6 remained unaltered (p ¼ 0.570, p ¼ 0.483 and
p ¼ 0.06, respectively).
3.6. Autoantibody-mediated in vivo deposition of IgG and
complement was unaltered by EndoS
In order to investigate the effect of EndoS on the binding of
autoantibodies to their target antigen and subsequent complement
recruitment, in vivo deposition of IgG, C3, and C5 at the DEJ were
visualized by direct IF microscopy of mouse ear skin obtained from
the three experimental groups: anti-mCOL7 IgG alone (Fig. 5aec),
EndoS-pretreated anti-mCOL7 IgG (Fig. 5def), and EndoS in
conjunction with anti-mCOL7 IgG (gei). The intensity of ﬂuores-
cence was quantiﬁed using ImageJ software. The levels of tissue-Fig. 4. Autoantibody-mediated intralesional inﬂammatory responses were inhibited by En
thology (aec) and quantiﬁcation of mRNA for different chemokines, cytokines, and cell mar
injected with untreated anti-mCOL7 IgG alone demonstrates signiﬁcantly higher inﬂammat
anti-mCOL7 IgG (b) or untreated anti-mCOL7 IgG together with 100 mg of EndoS (c). By RT-
monocytes (Mac-1) as well as of chemokines (KC and MIP) and inﬂammatory cytokines (TNF
mCOL7 IgG (n ¼ 8) compared to that of untreated anti-mCOL7 IgG-injected mice (n ¼ 11;bound IgG (Fig. 5j), C3 (Fig. 5k), and C5 (Fig. 5l) were not signiﬁ-
cantly different between the three experimental group. These data
indicate the EndoS did not interfere with autoantibody binding and
complement recruitment in vivo.
3.7. Therapeutic efﬁcacy of EndoS in immunization-induced
autoimmunity
To mimic the therapeutic situation in patients with
autoantibody-mediated disorders more closely, mice (n ¼ 50) were
immunized with a recombinant portion of the immunodominant
NC1 domain of murine type VII collagen. Mice that developed
a disease score of greater 2 (between 4 and 8 weeks after immu-
nization) were allocated to three groups: no treatment (n ¼ 16), i.p.
injection of 200 mg (n ¼ 11) and 400 mg (n ¼ 12) EndoS once per
week for 4 weeks, respectively. Mice in both EndoS treatment
groups developed signiﬁcantly less disease compared to non-
treated mice (Fig. 6aec). Importantly, disease progression was
already abrogated after the ﬁrst treatment week in the high-dose
group pointing to a direct effect of EndoS on the glycosylation
status of in vivo-bound autoantibody. In addition, the number of
mice in which disease activity decreased below the clinical score at
the time of treatment allocation was signiﬁcantly higher in the
EndoS groups (11 of 23) compared to the untreated mice (0 of 16;
p¼ 0.00065, Fisher’s exact test). Histopathological analysis showed
signiﬁcantly less inﬁltration of inﬂammatory cells including Gr-1
positive cells in dermal lesions of EndoS-treated mice compareddoS. Evaluation of the inﬂammatory response in ear skin was performed by histopa-
kers by RT-PCR (d). Representative histopathology pictures of skin obtained from mice
ory cell inﬁltration (a) compared with skin from mice injected with EndoS-pretreated
PCR, mRNA levels of makers for T cells (CD3), dendritic cell (CD11c) and macrophages/
a and IL-1b) were signiﬁcantly less in skin of mice that received EndoS-pretreated anti-
d; *p < 0.05, **p < 0.01, ***p < 0.001, t-test).
Fig. 5. Autoantibody-mediated in vivo deposition of IgG and complement was unaltered by EndoS. By direct immunoﬂuorescence microscopy of non-lesional mouse skin obtained
from mice injected with anti-COL7 IgG (a, b, c), EndoS-pretreated anti-COL7 IgG (d, e, f), and anti-mCOL7 IgG together with 100 mg of EndoS (g, h, i), in vivo deposits of IgG (a, d, g),
C3 (b, e, h) and C5 (c, f, i) at the dermal-epidermal junction were visualized. The intensity of ﬂuorescence was quantiﬁed using ImageJ software (j, IgG; k, C3; l, C5). No signiﬁcant
difference was observed between the 3 groups.
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deposits at the DEJ did not differ between any of the groups
(Fig. 6jem).3.8. EndoS does hydrolyze already-tissue-bound autoantibodies
Since EndoS injection reversed already established clinical
disease we further evaluated if EndoS could hydrolyze autoanti-
bodies that had already bound to their target antigen in the tissue.
IgG that was eluted from the skin following binding of pathogenic
anti-mCOL7 IgG and subsequent EndoS treatment showed sizereduction by SDS-PAGE and was unreactive by lectin blotting in
contrast to IgG eluted from the skin of mice that did not receive
EndoS (Fig. 7). Both eluted IgG fractions equally labeled the DEJ of
mouse skin by indirect IF microscopy (Fig. 7).3.9. EndoS modulates the expression of Fcg receptors in
autoantibody-mediated skin destruction
In mice that received EndoS-pretreated anti-mCOL7 IgG, mRNA
levels of the activating FcgRs were signiﬁcantly reduced compared
to mice injected with untreated anti-mCOL7 IgG (Fig. 8a). In
Fig. 6. Therapeutic efﬁcacy of EndoS in immunization-induced autoimmunity. Mice
that developed a disease score of greater 2 (between 4 and 8 weeks after
M. Hirose et al. / Journal of Autoimmunity 39 (2012) 304e314 311contrast, no differences were seen in mRNA levels of the inhibitory
FcgRIIB between the two groups (Fig. 8a). Similar data were ob-
tained when FcgR expression was related to the CD11c expression
in lesional skin, however, statistical signiﬁcance was not reached
(Fig. 8b).When FcgR expressionwas analyzed in the immunization-
induced model, EndoS injections resulted in reduced expression of
the activating FcgR and increased expression of FcgRIIB (Fig. 8c).
When related to the lesional expression of CD11c, a statistical
signiﬁcant downregulation was observed for FcgRIII and FcgRIV
whereas expression of FcgRIIB was signiﬁcantly increased (Fig. 8d).4. Discussion
EndoS has been identiﬁed as glycosidase that speciﬁcally
hydrolyzes the conserved N-linked glycan on IgG heavy chains
[30e32]. EndoS has a unique speciﬁcity for native IgG or IgG Fc
portion glycans compared to related endoglycosidases which are
speciﬁc for certain glycans that can be attached to any protein or
peptide, and which are enhanced by or require denaturation of the
protein backbone [32,33]. By hydrolysis of IgG glycan, binding
afﬁnity of the Fc portion of IgG to Fcg receptors (FcgRs) is modu-
lated. More precisely, EndoS-treated IgG has a considerably lower
afﬁnity to FcgRI, FcgRIIB, FcgRIII, and FcgRIV in mice [29]. Inter-
estingly, EndoS-hydrolyzed human IgG2 binds better to human
inhibitory receptor FcRIIB, while binding of all EndoS-hydrolyzed
IgG subclasses to activating receptors is lowered [28]. The thera-
peutic efﬁcacy of EndoS has previously been demonstrated in
different experimental autoimmune diseases induced by passive
transfer of antibodies, including rheumatoid arthritis [29,34],
immune-mediated thrombocytopenia [32], hemolytic anemia [39],
and ANCA-mediated glomerulonephritis [40]. Since EndoS does not
speciﬁcally target pathogenic autoantibodies but hydrolyzes the
entire pool of IgG, it may increase the risk for infections and
interfere with vaccination-induce immunity in human patients. On
the other hand, EndoS does not affect IgG’s F(ab)’ binding capacity
and activation of the classical complement system [32] leaving
intact large parts of the humoral immune defense system.
Furthermore, repetitive injections with EndoS can raise EndoS-
speciﬁc antibodies which may hamper its efﬁcacy.
Here, we extended the current knowledge about the mecha-
nisms of action of EndoS by the use of an immunization-induced
mouse model in which EndoS exerted its effect on autoantibodies
that had already bound to their autoantigen. In addition, expression
of the activating FcgRIII and FcgRIV in the skin lesions was down-
regulated whereas expression of the inhibiting FcgRIIB was upre-
gulated following EndoS treatment.
In the ﬁrst set of experiments, pretreatment of pathogenic
anti-mCOL7 IgG with EndoS resulted in a statistically signiﬁcant
reduction of dermal-epidermal separation in cryosections of mouseimmunization with a recombinant portion of the immunodominant NC1 domain of
murine type VII collagen) were allocated into three groups: no treatment (n ¼ 16) and
i.p. injection of 200 mg (n ¼ 11) or 400 mg (n ¼ 12) EndoS once per week for 4 weeks,
respectively. Mice in both EndoS treatment groups developed signiﬁcantly less disease
compared to non-treated mice (a; *p < 0.05). Representative clinical (bee), histo-
pathological (f,g,h,i), and immunopathological pictures (jem) of untreated mice (b, f, h,
j, l) and 400 mg EndoS-treated mice (c, e, g, i, k, m) are shown. Ear of a mouse that did
not receive EndoS (b) demonstrates more clinical disease, e.g. erythema and erosion,
compared with that was treated with 100 mg EndoS for 4 weeks (c). Clinical lesion on
a mouse tail at week 0 (before treatment, d) was completely healed after 4 weeks of
400 mg EndoS treatment (e). Histopathology of 400 mg EndoS-treated mice (g) shows
signiﬁcantly less inﬁltration of inﬂammatory cells including Gr-1 positive cells (gran-
ulocytes and monocytes) demonstrated by immunohistochemistry (i) in dermal
lesions compared with those of untreated mice (f, h). By direct IF microscopy, IgG (j, k)
and C3 (l, m) deposits at the DEJ did not differ between non-treated (j, l) and EndoS-
treated (k, m) groups.
Fig. 7. EndoS hydrolyzes tissue-bound autoantibodies IgG eluted from the skin of mice
that had received anti-mCOL7 IgG followed by injection of EndoS (þ) showed size
reduction by Coomassie Brilliant Blue staining (Stain) and lost reactivity by blotting
with LCA lectin (LCA blot). In comparison, IgG eluted from the skin of mice that were
injected with anti-mCOL7 IgG alone is shown (). Both eluted IgG fraction labeled the
dermal-epidermal junction by indirect immunoﬂuorescence microscopy on normal
murine skin (IF microscopy).
a b
c
d
Fig. 8. EndoS differently modulates the expression of activating and inhibitory Fcg receptor
Expression of activating FcgRs (FcgRI, FcgRIII, and FcgRIV) in EndoS-pretreated anti-mCOL
injected animals (a; *p < 0.05, t-test). Expression of FcgRIIB was signiﬁcantly increased
immunization-induced mouse model (c). Here, data reached statistical signiﬁcance only fo
expression of CD11c in both experimental models, a decrease of the activating and increas
immunization-induced model (d; *p < 0.05, t-test).
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bated with anti-mCOL7 IgG and subsequently with leukocytes from
healthy volunteers. Leukocytes attached to the DEJ and via the
release of elastase and matrix metalloproteinase-9 from gran-
ulocytes, the DEJ is split [26]. Based on these ﬁndings, in the next
set of experiments, a mouse model was used in which the injection
of anti-mCOL7 IgG reproduces the clinical and immunopathological
characteristics of the human disease [11]. In this model, the
pretreatment of pathogenic anti-mCOL7 IgG with EndoS prevented
clinical disease in all mice. When EndoS was administrated to mice
24 h after the injection of pathogenic anti-mCOL7 IgG, disease
activity was signiﬁcantly reduced. In order to control for a potential
effect of EndoS on the interaction of anti-mCOL7 IgG with mCOL7,s mRNA expression of Fc gamma receptors (FcgRs) in the lesional skin was determined.
7 IgG-injected mice was signiﬁcantly less compared with untreated pathogenic IgG-
following EndoS treatment (a; *p < 0.05, t-test). Similar data were obtained in the
r FcgRIV (c; *p < 0.05, t-test). When the lesional FcgR expression was related to the
e of the inhibitory FcgR(s) was seen (b, d). Statistical signiﬁcance was observed in the
M. Hirose et al. / Journal of Autoimmunity 39 (2012) 304e314 313the binding of anti-mCOL7 IgG to mouse skin was visualized by
direct IF microscopy. No signiﬁcant difference between skin of mice
that received anti-mCOL7 IgG alone, EndoS-treated anti-mCOL7
IgG, and pathogenic IgG, followed by EndoS injections, was
observed.
Furthermore, the binding of C3 and C5 to the DEJ remained
unaltered between the 3 groups. Previously, the binding of C3 and
C5 to the DEJ and the activation of the alternative pathway were
shown to be critical for disease development in this model [24].
EndoS has previously been shown to prevent binding of C1q,
a component of the classical pathway, to IgG-sensitized red blood
cells and subsequent hemolysis [39]. These data suggest that EndoS
may interfere with the binding of IgG to components of the clas-
sical, but not of the alternative pathway of complement activation.
In autoimmunity to mCOL7, complement deposition at the DEJ is
thought to be an essential step to attract inﬂammatory cells that
then become activated via the interaction between the Fc portion of
autoantibody and FcgR, which further enhances the local inﬂam-
mation, and ﬁnally leads to the release of proteases at the DEJ.
Regarding the pathogenic role of complement, we observed
unchanged levels of tissue-bound C3 and C5. It has been proposed
that anaphylatoxin C5a, which does not bind to tissue, and C5aR on
neutrophils may compose an ampliﬁcation loop for neutrophil
activation in ANCA-mediated nephritis model [41]. This speculates
that the less neutrophils due to inhibited the binding of FcgRs on
neutrophils and Fc part of the pathogenic IgG caused less C5a
production, and eventually reduce the disease severity at the lesion.
Our results indicate that EndoS treatment interferes with this
further enhancement of the local inﬂammation, thus inhibiting
dermal-epidermal separation.
Tomimic the situation of EBApatientsmore closely, in the last set
of experiments, an immunization-inducedmodel was employed. In
this model, SJL mice develop the clinical and immunopathological
hallmarks of thehumandisease 4e8weeks after immunizationwith
a recombinant fragment of the immunodominant NC1 domain of
mCOL7 [23]. This mouse model appeared to be particularly attrac-
tive since development of clinical disease depended on the depo-
sition of IgG2b autoantibodies to the DEJ [23] and EndoSwas shown
to only functionally impair IgG1 and IgG2b subclasses in mice [34].
In the present study, after disease onset, mice were allocated to 3
groups: 2 groups received weekly injections of different EndoS
doses and the third group was left untreated. In both treatment
groups, progression of the disease was abrogated. In fact, clinical
diseasewas reduced innearlyhalf of EndoS-treatedmice but innone
of untreated animals.
Importantly, in the high-dose EndoS group, progression of the
clinical disease activity was already inhibited one week after the
ﬁrst EndoS injection. In the low-dose EndoS group, this effect was
observed one week later. Since anti-mCOL7 IgG bound in murine
skin was previously found to remain in place for about 8 weeks by
investigating the off-spring of mice immunized with recombinant
mCOL7 [36], the clinical effect of EndoS in the present study is most
likely explained by a functional interaction of EndoS with tissue-
bound anti-mCOL7 IgG. This assumption was experimentally
corroborated when skin-bound anti-mCOL7 IgG eluted after in vivo
EndoS treatment was shown to be hydrolyzed in contrast to eluted
anti-mCOL7 IgG without preceding EndoS treatment. These ﬁnd-
ings have implications on a future therapeutic use of EndoS in
autoantibody-mediated diseases in which EndoS may interfere not
only with serum autoantibodies but also with autoantibodies that
have already bound to their target tissue.
Finally, we explored the effect of EndoS on the composition of
the inﬂammatory inﬁltrate and the differential expression of FcgR
in skin. We found mRNA levels of the different FcgR in the mouse
skin not to be equally affected by EndoS treatment, which has notpreviously been reported. In both the passive transfer model and
immunization-induced model, the activating FcgRs, including
FcgRI and low afﬁnity FcgRIII and FcgRIV were signiﬁcantly
downregulated, while the inhibiting FcgRIIB was upregulated
following EndoS treatment. This effect was shown to be in part
attributed to the reduction of the inﬂammatory inﬁltrate in the skin
lesions. In addition, a novel independent effect of EndoS on the
FcgR expression was observed. The pathogenic relevance of upre-
gulated activating FcgRs and downregulated FcgRIIB has previously
been shown in autoimmunity including human and experimental
rheumatoid arthritis, experimental arthritis and immune-complex
mediated nephritis [42,43] as well as, most recently, autoimmunity
to type VII collagen [44].
In conclusion, we extended the present knowledge about the
mechanisms of action of EndoS and favor the further exploration of
enzymatic autoantibody glycan hydrolysis as novel, therapeutic
option in severe autoantibody-mediated disease.
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